BioLineRx Ltd.

Regulatory Filings • Nov 22, 2011

_________ false

C002������� �� ��� ��"�2PublicBIOLINE RX LTD8688Corporation no: 513398750Stock Exchange/Market: ������� �� ���2271380����� 19 , ������� 91450 , ,Tel: 02-5489100 , 02-5489116 Fax: 02-5489101E.mail address: info@BioLineRx.comDate of transmission: 22/11/2011              Time of broadcast: 09:05 09:05:26

Reference: 2011-02-334236

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on BioLineRx Announces Receipt of Approval in India to Commence Phase II/III CLARITY Clinical Trial of BL-1020 for Treatment of Schizophrenia
6-K_Nov-22-2011_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity:
Date of revision of form structure: 04/09/2011
- - -
Name of the Signatory: : Serlin Philip Adam , Position of Signatory in the reporting corporation: Chief Financial Officer , Name of Employer Company: .
Hartum St Telephone: 02-5489100 , Facsimile: 02-5489101 , E-mail: phils@biolinerx.com 2